Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus
Retrieved on:
Tuesday, October 26, 2021
Tripura Merger Agreement, LinkedIn, MSON, Neurosurgery, Twitter, Evidence-based medicine, Agreement, Patient, Private Securities Litigation Reform Act, Sumathi Best Television Current Reporting Award, SEC, Risk, Nature, Annual report, Plan, Forward-looking statement, Company, Regenerative medicine, U.S. Securities and Exchange Commission, Nasdaq, Acquisition, Therion, VWAP, Proxy, Uncertainty, GLOBE, Innovation, Physician, Holding company, Medical imaging, Risk management
We are pleased by the outcome of todays vote and thank our stockholders for supporting the acquisition, said Ken Reali, Chief Executive Officer, Bioventus.
Key Points:
- We are pleased by the outcome of todays vote and thank our stockholders for supporting the acquisition, said Ken Reali, Chief Executive Officer, Bioventus.
- We are excited to welcome the Misonix team to Bioventus.
- The aggregate share consideration to Misonix stockholders is expected to represent approximately 25% of the combined company on a fully-diluted basis.
- Readers should also carefully review the risk factors described in other documents that Bioventus and Misonix file from time to time with the SEC.